Abstract: The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition provides a rapid onset of action while having low irritation potential in the oral mucosa.
Type:
Grant
Filed:
November 24, 2010
Date of Patent:
November 13, 2012
Assignee:
Orion Corporation
Inventors:
Mirja Huhtinen, Piritta Koistinen, Lasse Leino, Maria Rantala, Helena Kaukinen, Kaija Af Ursin
Abstract: A hydrodynamic bearing includes a housing defining a central axis, a pad slidable relative to the housing in a direction substantially parallel to the central axis, a cylinder defined in one of the housing and the pad, a lubricant port in fluid communication with the cylinder, and a piston at least partially positioned in the cylinder. The piston is movable within the cylinder between a retracted position and an extended position in response to a flow of lubricant through the lubricant port to vary an axial spacing between the pad and the housing.
Abstract: A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.
Type:
Grant
Filed:
May 12, 2005
Date of Patent:
September 13, 2011
Assignee:
Orion Corporation
Inventors:
Heimo Haikala, Jouko Levijoki, Piero Pollesello, Carola Tilgmann
Abstract: Compounds of formula (I), wherein R1-R4, X, Y and Z are as defined in claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.
Type:
Application
Filed:
July 17, 2006
Publication date:
April 14, 2011
Applicant:
Orion Corporation
Inventors:
Marko AHLMARK, Reijo BACKSTROM, Anne LUIRO, Jarmo PYSTYNEN, Eija TIAINEN
Abstract: The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition provides a rapid onset of action while having low irritation potential in the oral mucosa.
Type:
Application
Filed:
November 24, 2010
Publication date:
March 24, 2011
Applicant:
Orion Corporation
Inventors:
Mirja Huhtinen, Piritta Koistinen, Lasse Leino, Maria Rantala, Helena Kaukinen, Kaija AF Ursin
Abstract: The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition provides a rapid onset of action while having low irritation potential in the oral mucosa.
Type:
Grant
Filed:
November 3, 2005
Date of Patent:
January 4, 2011
Assignee:
Orion Corporation
Inventors:
Mirja Huhtinen, Piritta Koistinen, Lasse Leino, Maria Rantala, Helena Kaukinen, Kaija Af Ursin
Abstract: Novel prodrugs of MPV-2426, methods for preparing said prodrug forms, pharmaceutical compositions containing such prodrug forms, and methods for using the prodrug forms. A compound of general formula (I), or pharmaceutically acceptable salts or hydrates thereof, wherein R represents unsubstituted or substituted lower alkyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted lower alkylamino or a saturated five or six membered heterocyclic group containing one or two nitrogen atoms.
Type:
Grant
Filed:
December 5, 2003
Date of Patent:
July 20, 2010
Assignee:
Orion Corporation
Inventors:
Tomi Järvinen, Riku Niemi, Juhani Huuskonen
Abstract: A method of isolating detomidine (I) hydrochloride as a crystalline salt is provided. The method comprises hydrogenating in the presence of a catalyst of compound of formula (II) in aqueous solution comprising hydrochloric acid, concentrating the solution by distillation, optionally adding hydrochloric acid to the concentrated solution, cooling the concentrated solution and recovering the crystallized detomidine hydrochloride.
Abstract: A compound of formula I, wherein X, Z, R1 to R10, R15, R16, m, n, r and t are as defined in claim 1, or a pharmaceutically acceptable salt or ester thereof, useful as an alpha-2 antagonist. The compounds of formula I can be used for the treatment of diseases or conditions where antagonists of alpha-2 adrenoceptors are indicated to be effective.
Type:
Grant
Filed:
April 3, 2003
Date of Patent:
September 22, 2009
Assignee:
Orion Corporation
Inventors:
David Din Belle, Reija Jokela, Arto Tolvanen, Antti Haapalinna, Arto Karjalainen, Jukka Sallinen, Jari Ratilainen
Abstract: Levosimendan, or (?)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been mentioned for the treatment of congestive heart failure, is useful in the treatment of septic shock.
Type:
Grant
Filed:
June 28, 2001
Date of Patent:
February 3, 2009
Assignee:
Orion Corporation
Inventors:
Anders Oldner, Michael Wanecek, Eddie Weitzberg, Anders Rudehill
Abstract: Therapeutically active compounds of formula (I) or (II): wherein the variables in formulas (I) and (II) are defined in the description, and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.
Type:
Grant
Filed:
January 9, 2004
Date of Patent:
January 27, 2009
Assignee:
Orion Corporation
Inventors:
Leena Otsomaa, Tuula Koskelainen, Arto Karjalainen, Sirpa Rasku, Piero Pollesello, Jouko Levijoki
Abstract: The present invention relates to a method for the treatment of sensorimotor dysfunctions caused by brain trauma with an inhibitor of prolyl oligopeptidase or a pharmaceutically acceptable ester or salt thereof.
Abstract: Therapeutically active compounds of formula (I): wherein the variables shown in formula (I) are defined in the disclosure; and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of the Na+/Ca2+ exchange mechanism.
Type:
Grant
Filed:
July 10, 2002
Date of Patent:
September 16, 2008
Assignee:
Orion Corporation
Inventors:
Tuula Koskelainen, Leena Otsomaa, Arto Karjalainen, Pekka Kotovuori, Jukka Tenhunen, Sirpa Rasku, Pentti Nore, Eija Tiainen, Olli Törmäkangas